Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $300.73 billion. The enterprise value is $327.23 billion.
| Market Cap | 300.73B |
| Enterprise Value | 327.23B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024, before market open.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | Sep 16, 2024 |
Share Statistics
Merck & Co. has 2.53 billion shares outstanding. The number of shares has increased by 0.28% in one year.
| Shares Outstanding | 2.53B |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 78.62% |
| Float | 2.53B |
Valuation Ratios
The trailing PE ratio is 22.03 and the forward PE ratio is 13.90. Merck & Co.'s PEG ratio is 0.33.
| PE Ratio | 22.03 |
| Forward PE | 13.90 |
| PS Ratio | 4.81 |
| Forward PS | 4.41 |
| PB Ratio | 6.90 |
| P/FCF Ratio | 22.87 |
| PEG Ratio | 0.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.85, with an EV/FCF ratio of 24.89.
| EV / Earnings | 23.82 |
| EV / Sales | 5.24 |
| EV / EBITDA | 13.85 |
| EV / EBIT | 16.56 |
| EV / FCF | 24.89 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.47 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 2.87 |
| Interest Coverage | 15.94 |
Financial Efficiency
Return on equity (ROE) is 33.38% and return on invested capital (ROIC) is 15.73%.
| Return on Equity (ROE) | 33.38% |
| Return on Assets (ROA) | 11.38% |
| Return on Capital (ROIC) | 15.73% |
| Revenue Per Employee | $867,778 |
| Profits Per Employee | $190,778 |
| Employee Count | 72,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.44 |
Taxes
In the past 12 months, Merck & Co. has paid $1.50 billion in taxes.
| Income Tax | 1.50B |
| Effective Tax Rate | 9.82% |
Stock Price Statistics
The stock price has increased by +10.04% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +10.04% |
| 50-Day Moving Average | 118.47 |
| 200-Day Moving Average | 122.19 |
| Relative Strength Index (RSI) | 56.08 |
| Average Volume (20 Days) | 8,439,121 |
Short Selling Information
The latest short interest is 25.91 million, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 25.91M |
| Short Previous Month | 26.72M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.02% |
| Short Ratio (days to cover) | 2.47 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $62.48 billion and earned $13.74 billion in profits. Earnings per share was $5.39.
| Revenue | 62.48B |
| Gross Profit | 47.35B |
| Operating Income | 19.77B |
| Pretax Income | 15.23B |
| Net Income | 13.74B |
| EBITDA | 23.63B |
| EBIT | 19.77B |
| Earnings Per Share (EPS) | $5.39 |
Balance Sheet
The company has $11.35 billion in cash and $37.79 billion in debt, giving a net cash position of -$26.43 billion or -$10.43 per share.
| Cash & Cash Equivalents | 11.35B |
| Total Debt | 37.79B |
| Net Cash | -26.43B |
| Net Cash Per Share | -$10.43 |
| Equity (Book Value) | 43.65B |
| Book Value Per Share | 17.19 |
| Working Capital | 12.15B |
Cash Flow
In the last 12 months, operating cash flow was $16.69 billion and capital expenditures -$3.54 billion, giving a free cash flow of $13.15 billion.
| Operating Cash Flow | 16.69B |
| Capital Expenditures | -3.54B |
| Free Cash Flow | 13.15B |
| FCF Per Share | $5.19 |
Margins
Gross margin is 75.79%, with operating and profit margins of 31.64% and 21.98%.
| Gross Margin | 75.79% |
| Operating Margin | 31.64% |
| Pretax Margin | 24.41% |
| Profit Margin | 21.98% |
| EBITDA Margin | 37.82% |
| EBIT Margin | 31.64% |
| FCF Margin | 21.04% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.60%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.60% |
| Dividend Growth (YoY) | 5.48% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 57.18% |
| Buyback Yield | -0.28% |
| Shareholder Yield | 2.32% |
| Earnings Yield | 4.57% |
| FCF Yield | 4.37% |
Analyst Forecast
The average price target for Merck & Co. is $134.58, which is 13.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $134.58 |
| Price Target Difference | 13.44% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 5.98% |
| EPS Growth Forecast (5Y) | 146.04% |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.57 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.57 |
| Piotroski F-Score | 7 |